Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Steger

Showing results (241-250 of 320) with videos related to

Pageof 32
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?G J Locker, G G Steger, M F Gnant, et al.
British Journal of Cancer|June 1, 2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case seriesF Zagouri, T N Sergentanis, V Koutoulidis, et al.
Anti-Cancer Drugs|November 5, 2003
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinomaCatharina Wenzel, Gottfried J Locker, Rupert Bartsch, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerT Brodowicz, W J Kostler, R Möslinger, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerI Lang, M J Inbar, Z Kahán, et al.
British Journal of Haematology|November 11, 1999
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disordersG J Locker, S Kapiotis, M Veitl, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 9, 2006
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysisRupert Bartsch, Sabine Fromm, Margaretha Rudas, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 1999
Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactionsG J Locker, R M Mader, B Rizovski, et al.
Anticancer Research|May 25, 2004
Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancerWolfgang J Köstler, Günther G Steger, Afschin Soleiman, et al.
Pageof 32

Showing results (241-250 of 320) with videos related to

Sort By:
Pageof 32
Journal of Immunotherapy (Hagerstown, Md. : 1997)|January 30, 1999
Induction of immunomediated diseases by recombinant human granulocyte-macrophage colony-stimulating factor during cancer treatment?G J Locker, G G Steger, M F Gnant, et al.
British Journal of Cancer|June 1, 2013
Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case seriesF Zagouri, T N Sergentanis, V Koutoulidis, et al.
Anti-Cancer Drugs|November 5, 2003
Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinomaCatharina Wenzel, Gottfried J Locker, Rupert Bartsch, et al.
Breast (Edinburgh, Scotland)|February 18, 2004
Single-agent gemcitabine as second- and third-line treatment in metastatic breast cancerT Brodowicz, W J Kostler, R Möslinger, et al.
The Lancet Regional Health. Europe|December 20, 2024
Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trialAlexios Matikas, Andri Papakonstantinou, Sibylle Loibl, et al.
European Journal of Cancer (Oxford, England : 1990)|May 30, 2012
Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancerI Lang, M J Inbar, Z Kahán, et al.
British Journal of Haematology|November 11, 1999
Activation of endothelium by immunotherapy with interleukin-2 in patients with malignant disordersG J Locker, S Kapiotis, M Veitl, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 9, 2006
Intensified local treatment and systemic therapy significantly increase survival in patients with brain metastases from advanced breast cancer - a retrospective analysisRupert Bartsch, Sabine Fromm, Margaretha Rudas, et al.
The Journal of Pharmacology and Experimental Therapeutics|June 25, 1999
Negative chronotropic effects of fentanyl attenuate beneficial effects of dobutamine on oxygen metabolism: hemodynamic and pharmacokinetic interactionsG J Locker, R M Mader, B Rizovski, et al.
Anticancer Research|May 25, 2004
Monitoring of serum Her-2/neu predicts histopathological response to neoadjuvant trastuzumab-based therapy for breast cancerWolfgang J Köstler, Günther G Steger, Afschin Soleiman, et al.
Pageof 32